The latest developments in the MATRICS process

Dr. Harvey is Professor of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia.
Psychiatry 06/2010; 7(6):49-52.
Source: PubMed

ABSTRACT The Measurement and Treatment Research to Improve Cognition in Schizophrenia Research process has led to several developments in the assessment of cognitive functioning for schizophrenia-treatment studies. The first development was the development of a consensus cognitive battery and a United States Food and Drug Administration-endorsed research design. Since the development of the cognitive battery, interest has been spurred in clinical trials in different countries and the development of co-primary functional outcomes measures for these. The MATRICS Consensus Cognitive Battery has been translated into 11 different languages and is being translated into even more. A study has been completed that compared the usefulness of multiple potential co-primary measures, suggesting that the University of California San Diego Performance-Based skills assessment, version II (UPSA-II) is the most suitable for studies conducted in English. These findings suggest that reliable performance-based measures that are easy to administer and highly correlated with cognitive functioning are now available for use in treatment studies.

Download full-text


Available from: Keith H Nuechterlein, Feb 15, 2015
  • Source
    • "The unmet medical need to find new approaches for the pharmacotherapy of the cognitive deficit in schizophrenia facilitated the establishment of MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia , and CNTRICS (Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia) initiatives (Carter, 2005; Carter and Barch, 2007; Carter et al., 2008; Harvey et al., 2010). As a result of the MATRICS collaboration a consensus of opinion on the core cognitive deficits in schizophrenia patients has emerged. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Classical antipsychotics, e.g. haloperidol, chlorpromazine, are potent at controlling the positive symptoms of schizophrenia but frequently elicit extrapyramidal motor side-effects. The introduction of atypical antipsychotics such as risperidone, olanzapine and clozapine has obviated this problem, but none of the current drugs seem to improve the cognitive deficits accompanying schizophrenia. Thus there is an unmet need for agents that not only suppress the psychotic symptoms but also ameliorate the impairment of cognition. Here, we report the preclinical properties of a candidate antipsychotic, Egis-11150, that shows marked pro-cognitive efficacy. Egis-11150 displayed high affinity for adrenergic α(1), α(2c), 5-HT(2A) 5-HT(7), moderate affinity for adrenergic α(2a) and D(2) receptors. It was a functional antagonist on all of the above receptors, with the exception of 5-HT(7) receptors, where it was an inverse agonist. Phencyclidine-induced hypermotility in mice and inhibition of conditioned avoidance response in rats were assessed to estimate efficacy against the positive and social withdrawal test in rats was used to predict efficacy against the negative symptoms of schizophrenia. Passive-avoidance learning, novel object recognition and radial maze tests in rats were used to assess pro-cognitive activity, while phencyclidine-induced disruption of prepulse inhibition in mice was examined to test for effects on attention. Egis-11150 (0.01-0.3 mg/kg, ip.) was effective in all of the preclinical models of schizophrenia examined. Moreover, a robust pro-cognitive profile was apparent. In summary, work in preclinical models indicates that Egis-11150 is a potential treatment for controlling the psychosis as well as the cognitive dysfunction in schizophrenia. This article is part of a Special Issue entitled 'Cognitive Enhancers'.
    Neuropharmacology 07/2012; 64(1):254-63. DOI:10.1016/j.neuropharm.2012.07.017 · 4.82 Impact Factor
  • Source
    • "The executive functioning measures in the consensus battery included tests of working memory (letter-number and spatial span tests), vigilance (continuous performance) and reasoning-problem solving (Neuropsychological Assessment Battery mazes test). MATRICS' purpose, in part, was to have a repeatable battery which could be used to assess interventions over a short course clinical trial (Buchanan, Keefe et al. 2010; Harvey, Green et al. 2010). As a result of this short term, global cognitive functioning assessment aim, MATRICS might best be considered a baseline battery, useful for cross-study comparison, but with a breadth and depth too narrow for the assessment of trajectories or able to meaningfully capture any one set of abilities completely. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Executive dysfunction is a core feature of schizophrenia, but our understanding of the developmental course of this neuropsychological domain in the disease remains largely unexplored. A review of the research evidence points to a number of persistent debates about the course of executive functioning and its relation to illness course. A better understanding of the neurocognitive trajectories of executive functioning in schizophrenia could help identify the risk and modifying factors that influence the onset, severity and course of disease, and the chance to re-direct or re-shape that course and improve outcomes. To accomplish this requires assessment of the diverse and integrated nature of those abilities, and the changes over time in those abilities requires multiple instruments and techniques in order to improve the research methods and understanding of an important area of impairment in schizophrenia.
    International journal of developmental neuroscience: the official journal of the International Society for Developmental Neuroscience 11/2010; 29(3):237-43. DOI:10.1016/j.ijdevneu.2010.11.003 · 2.92 Impact Factor
  • Article: attention
    [Show abstract] [Hide abstract]
    ABSTRACT: Functionally independent components of early
Show more